Trial Outcomes & Findings for Fat Reduction in the Submandibular/Submental Area (NCT NCT02700165)
NCT ID: NCT02700165
Last Updated: 2021-11-16
Results Overview
Change in the treated vs. untreated areas will be assessed by observation of changes in surface contour and/or fat volume by an independent photo review of pre-treatment and post-treatment images of the treated areas. Reviewers will be practicing dermatologists or plastic surgeons. All reviewers will be blinded to post-treatment vs. baseline untreated area. The order in which images will be presented will be randomized; for each subject placement of the baseline, pre-treatment image will be randomized for each pair of subject images. Reviewers will be asked to select the baseline photos for each subject photo series and record selections on a data collection form. Success is defined as 70% correct identification of pre-treatment images by at least 70% correct identification of pre-treatment images by two out of three reviewers.
COMPLETED
NA
14 participants
Baseline (pre-treatment) and 12 weeks post treatment
2021-11-16
Participant Flow
Subjects seeking reduction of fat in the submental and submandibular area were recruited from the general population.
Participant milestones
| Measure |
CoolSculpting With CoolMini Applicator for Fat Reduction in the Chin
Per protocol, subjects were permitted to receive up to 3 CoolSculpting treatments on the submental and submandibular area at each of two treatment sessions spaced 6 weeks apart. At each treatment session, subjects were treated with the CoolSculpting device programmed for a specified protocol-defined time and temperature. All subjects received 2 cooling cycles at the first treatment session. At the second treatment visit, 12 subjects received 2 cooling cycles and 2 received 1 cycle.
|
|---|---|
|
Overall Study
STARTED
|
14
|
|
Overall Study
COMPLETED
|
14
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Fat Reduction in the Submandibular/Submental Area
Baseline characteristics by cohort
| Measure |
CoolSculpting With CoolMini Applicator
n=14 Participants
ZELTIQ CoolSculpting System Treatment Group
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
14 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
|
Age, Continuous
|
50.5 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
12 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
African American
|
2 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian
|
0 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Caucasian
|
12 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
0 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Other
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
14 Participants
n=5 Participants
|
|
Body Mass Index
|
33.1 kg/m^2
n=5 Participants
|
PRIMARY outcome
Timeframe: Baseline (pre-treatment) and 12 weeks post treatmentPopulation: All subjects were included in the analysis population.
Change in the treated vs. untreated areas will be assessed by observation of changes in surface contour and/or fat volume by an independent photo review of pre-treatment and post-treatment images of the treated areas. Reviewers will be practicing dermatologists or plastic surgeons. All reviewers will be blinded to post-treatment vs. baseline untreated area. The order in which images will be presented will be randomized; for each subject placement of the baseline, pre-treatment image will be randomized for each pair of subject images. Reviewers will be asked to select the baseline photos for each subject photo series and record selections on a data collection form. Success is defined as 70% correct identification of pre-treatment images by at least 70% correct identification of pre-treatment images by two out of three reviewers.
Outcome measures
| Measure |
CoolSculpting With CoolMini Applicator
n=14 photos
ZELTIQ CoolSculpting System Treatment Group
|
|---|---|
|
Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers
|
11 photos
|
PRIMARY outcome
Timeframe: Enrollment through the 12 week final follow-up visitPopulation: The per-protocol population of 14 subjects was analyzed.
The primary safety endpoint is the count of unanticipated adverse device effects (UADEs) reported in the study period. It is expected there will be zero UADEs.
Outcome measures
| Measure |
CoolSculpting With CoolMini Applicator
n=14 Participants
ZELTIQ CoolSculpting System Treatment Group
|
|---|---|
|
The Number of Unanticipated Adverse Device Effects (UADE) Reported
|
0 UADEs
|
SECONDARY outcome
Timeframe: Baseline and 12 week post-treatmentCaliper measurements will be collected prior to treatment (pre-treatment) and at the 12-week follow-up visit. The caliper measurement process involves pinching the tissue within the treatment area in order to obtain the measurement, thereby folding the tissue and doubling the fat layer thickness. Measurements were taken with subjects standing in a neutral position. Measured values (mm) will be halved to reflect single fat layer change and will not take into account the fold of tissue during the measurement process. The fat layer measured pre-treatment will be compared to the 12-week post-treatment measurement.
Outcome measures
| Measure |
CoolSculpting With CoolMini Applicator
n=14 Participants
ZELTIQ CoolSculpting System Treatment Group
|
|---|---|
|
Change in Fat Layer Thickness of the Submental Area as Measured by Caliper
|
-2.3 millimeters fat layer change
Standard Deviation 0.8
|
SECONDARY outcome
Timeframe: 12 weeks post-treatmentPopulation: The per-protocol population of 14 subjects was included the analysis group.
Subject satisfaction as assessed by questionnaires administered at 12 weeks. Subjects will be asked to determine overall satisfaction with the treatment using a 5-point scale and free-text response options on a questionnaire. The choice options will be 1 = very dissatisfied, 2- dissatisfied, 3 - not sure, 4- satisfied and 5- very satisfied. Positive responses to questionnaire statements (score 4 or 5) will be used to assess satisfaction with the CoolSculpting procedure.
Outcome measures
| Measure |
CoolSculpting With CoolMini Applicator
n=14 Participants
ZELTIQ CoolSculpting System Treatment Group
|
|---|---|
|
Subject Satisfaction
Agree/strongly agree appearance improved
|
11 Participants
|
|
Subject Satisfaction
Procedure comfortable/very comfortable
|
7 Participants
|
|
Subject Satisfaction
Visible fat/very visible fat reduction
|
10 Participants
|
|
Subject Satisfaction
Agree/strongly agree appearance more youthful
|
9 Participants
|
|
Subject Satisfaction
Agree/strongly agree chin looked more toned
|
12 Participants
|
|
Subject Satisfaction
Agree/strongly agree less self-conscious of chin
|
11 Participants
|
|
Subject Satisfaction
Agree/strongly agree result was as expected
|
11 Participants
|
|
Subject Satisfaction
Satisfied/very satisfied with CoolSculpting
|
13 Participants
|
|
Subject Satisfaction
Would recommend procedure to a friend
|
13 Participants
|
Adverse Events
CoolSculpting With CoolMini Applicator
Serious adverse events
| Measure |
CoolSculpting With CoolMini Applicator
n=14 participants at risk
The ZELTIQ CoolSculpting System Treatment Group
|
|---|---|
|
Musculoskeletal and connective tissue disorders
Hip Replacement
|
7.1%
1/14 • Number of events 1 • Adverse event data was collected from enrollment through the 12 week final follow-up visit.
|
Other adverse events
| Measure |
CoolSculpting With CoolMini Applicator
n=14 participants at risk
The ZELTIQ CoolSculpting System Treatment Group
|
|---|---|
|
Skin and subcutaneous tissue disorders
Rash on face and neck
|
7.1%
1/14 • Number of events 1 • Adverse event data was collected from enrollment through the 12 week final follow-up visit.
|
|
Surgical and medical procedures
Ear pain
|
7.1%
1/14 • Number of events 1 • Adverse event data was collected from enrollment through the 12 week final follow-up visit.
|
|
General disorders
Tongue tingling
|
7.1%
1/14 • Number of events 1 • Adverse event data was collected from enrollment through the 12 week final follow-up visit.
|
Additional Information
Kerrie Jiang, Exective Director, Regulatory, Clinical and Medical Affairs
Zeltiq Aesthetics
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place